Leerink Partners maintains Replimune Group at Outperform, raises price target to $31 from $19

Leerink Partners kept Replimune Group at Outperform, raising its price target to $31 from $19, a 63.2% increase. The new target implies a 93.0% upside from the Oct 28 close of $16.06.

Original reporting
Published Oct 29, 2026, 6:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 7:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leerink Partners maintains Replimune Group at Outperform, raises price target to $31 from $19 — source image
Decision brief

The 30-second read

Low
01

Why it matters

Analyst rating changes can move thinly‑traded stocks, especially in biotech.

02

Market read

The upgrade may prompt short‑term buying pressure on RPLM.

03

What to watch

No new clinical data were released; the upgrade relies on expectations rather than concrete results.

Relevance 5/10Novelty 4/10Timing: today

Background

Replimune Group is a clinical‑stage biotech focused on oncolytic virus therapies.

Market effects

May lift sentiment in the biotech sector as analysts reassess small‑cap immunotherapy stocks.

Limited to U.S. markets where the stock trades.

Minimal global impact.

Counterpoint

The price target increase could be overly optimistic if upcoming trial data disappoint.

Key entities

  • Leerink Partners

    Equity research firm that issued the rating upgrade.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.